Merck and Moderna reported positive Phase 3 results for INTerpath-001 (NCT05933577), testing their bespoke mRNA therapeutic intismeran (mRNA-4157/V940) in combination with Merck’s pembrolizumab (Keytruda) in stage IIB–IV cutaneous melanoma. The companies said the mRNA-lipid nanoparticle approach reduced recurrence, metastasis, and death signals compared with pembrolizumab alone, marking the first bespoke mRNA immunotherapy to pass the Phase 3 hurdle described in the report. The trial enrolled more than 1,100 participants and compared pembrolizumab monotherapy versus combination dosing with intismeran, with stopping rules tied to unacceptable toxicity. The dataset frames the finding as a potential regulatory inflection point for individualized mRNA cancer treatment. For the sector, the outcome strengthens the case that patient-specific design—enabled by Moderna’s AI algorithm—is moving from concept to late-stage evidence. It also intensifies discussion about how regulators will evaluate personalization and manufacturing consistency. The durability of the efficacy signal and the safety profile will be key follow-through items as the companies move toward submissions.